This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic research hub

CAALL-F01: a French protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents

This study looks at a new way to treat a type of blood cancer called acute lymphoblastic leukemia (ALL) in children and teenagers (aged 12 months to under 18 years). It’s testing different ways of giving a medicine called pegaspargase to see how well it works and if it causes side effects.